Clinical Efficacy of Guanxinning Tablets in Patients with Acute Myocardial Infarction After Percutaneous Coronary Intervention
10.13359/j.cnki.gzxbtcm.2025.10.006
- VernacularTitle:冠心宁片治疗急性心肌梗死经皮冠状动脉介入治疗术后患者的临床疗效
- Author:
Sihan LIU
1
;
Ding YUAN
;
Danchun SUN
Author Information
1. 广州中医药大学第五临床医学院,广东 广州 510405
- Keywords:
Guanxinning Tablets;
acute myocardial infarction(AMI);
percutaneous coronary intervention;
qi stagnation and blood stasis syndrome;
myocardial injury markers;
inflammatory response;
quality of life;
safety
- From:
Journal of Guangzhou University of Traditional Chinese Medicine
2025;42(10):2400-2406
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy of Guanxinning Tablets(composed of Salviae Miltiorrhizae Radix et Rhizoma and Chuangxiong Rhizoma)in patients with acute myocardial infarction(AMI)after percutaneous coronary intervention(PCI)presenting with qi stagnation and blood stasis syndrome.Methods Eighty AMI patients who underwent PCI and were diagnosed with qi stagnation and blood stasis syndrome were enrolled from Guangdong Second Traditional Chinese Medicine Hospital between January 2024 and December 2024.Patients were randomly divided into a control group(n=40)and an observation group(n=40)using a random number table.The control group received standard post-PCI treatment(Aspirin 0.1 g qd+Clopidogrel 75 mg qd),while the observation group received additional Guanxinning Tablets for 8 weeks.Serum myocardial injury markers[troponin I(TnI),N-terminal pro-B-type natriuretic peptide(NT-proBNP)],novel inflammatory indices[systemic immune-inflammation index(SII),systemic inflammation response index(SIRI)],and Seattle Angina Questionnaire(SAQ)scores were assessed before and after treatment.Clinical efficacy and safety were evaluated.Results(1)Efficacy:After 8 weeks,the total effective rate was 97.50％(39/40)in the observation group versus 92.50％(37/40)in the control group,showing a non-significant trend favoring the observation group(P＞0.05,by chi-square test).(2)Myocardial injury markers:Both groups exhibited significant improvements in TnI and NT-proBNP levels(P＜0.05),with greater improvements in the observation group(P＜0.05).(3)Inflammatory indices:SII and SIRI levels were significantly improved in both groups(P＜0.05),with superior reductions in the observation group(P＜0.01).(4)Quality of life:SAQ scores in the dimensions of physical limitation,angina stability,angina frequency,treatment satisfaction,and disease perception were improved in both groups(P＜0.05),and the observation group showed significantly better outcomes(P＜0.05 or P＜0.01).(5)Safety:No severe cardiovascular adverse events or allergic reactions occurred in either group.Mild adverse events(e.g.,dizziness,gastrointestinal discomfort)occurred in 5.00％(2/40)of both groups(P＞0.05).Conclusion Guanxinning Tablets combined with conventional post-PCI therapy significantly improve clinical symptoms,cardiac function,inflammatory response,and quality of life in AMI patients with qi stagnation and blood stasis syndrome,with excellent safety and tolerability.
